ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer

被引：0
|
作者：
Mc Leer, A. [1 ]
Duruisseaux, M. [2 ]
Pinsolle, J. [2 ]
Dubourg, S. [1 ]
Mondet, J. [1 ]
Phillips-Houlbracq, M. [2 ]
Magnat, N. [1 ]
Faure, J. [3 ]
Chatagnon, A. [3 ]
de Fraipont, F. [1 ]
Levra, M. Giaj [2 ]
Toffart, A. C. [2 ]
Ferretti, G. [4 ]
Brambilla, E. [5 ]
Hainaut, P. [1 ]
Moro-Sibilot, D. [2 ]
Lantuejoul, S. [5 ]
机构：
[1] Hop Michallon, CHU Grenoble, Canc Mol Genet Platform, La Tronche, France
[2] Hop Michallon, CHU Grenoble, Thorac Oncol, La Tronche, France
[3] Hop Michallon, CHU Grenoble, Mol Biol Platform, La Tronche, France
[4] Hop Michallon, CHU Grenoble, Radiol & Imaging Dept, La Tronche, France
[5] Hop Michallon, CHU Grenoble, Dept Pathol, La Tronche, France
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1336P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066), IN ALK-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Camidge, D. R.
    Bang, Y.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Solomon, B.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
  • [22] Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
    Ock, Chan-Young
    Yoo, Shin-Hye
    Keam, Bhumsuk
    Kim, Miso
    Kim, Tae Min
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Chung, Doo Hyun
    Heo, Dae Seog
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (05): : 1116 - +
  • [23] Future options for ALK-positive non-small cell lung cancer
    Iacono, Daniela
    Chiari, Rita
    Metro, Giulio
    Bennati, Chiara
    Bellezza, Guido
    Cenci, Matteo
    Ricciuti, Biagio
    Sidoni, Angelo
    Baglivo, Sara
    Minotti, Vincenzo
    Crino, Lucio
    LUNG CANCER, 2015, 87 (03) : 211 - 219
  • [24] Brigatinib as a treatment of ALK-positive non-small cell lung cancer
    De Carlo, Elisa
    Stanzione, Brigida
    Del Conte, Alessandro
    Revelant, Alberto
    Bearz, Alessandra
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (05): : 299 - 305
  • [25] Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer
    Nishi, Koichi
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
    Barrows, Stephanie M.
    Wright, Kelly
    Copley-Merriman, Catherine
    Kaye, James A.
    Chioda, Marc
    Wiltshire, Robin
    Torgersen, Knut Martin
    Masters, Elizabeth T.
    LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 11 - 20
  • [27] Next Generation Sequencing Reveals Genomic Heterogenity of ALK Fusion Breakpoints in Non-Small Cell Lung Cancer
    Rosenbaum, Jason N.
    Branson, Julie
    Cottrell, Catherine E.
    Pfeifer, John D.
    Kulkarm, Shashikant
    Duncavage, Eric J.
    MODERN PATHOLOGY, 2016, 29 : 481A - 482A
  • [28] Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers
    Chuang, Jody C.
    Neal, Joel W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (05) : 639 - 641
  • [29] Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients
    Shaohua Cui
    Yizhuo Zhao
    Aiqin Gu
    Xiaoxiao Ge
    Yanyan Song
    Wei Zhang
    Yuqing Lou
    Lili Dong
    Baohui Han
    Liyan Jiang
    Medical Oncology, 2015, 32
  • [30] Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients
    Bendaly, Edmond
    Dalal, Anand A.
    Culver, Kenneth
    Galebach, Philip
    Bocharova, Iryna
    Foster, Rebekah
    Sasane, Medha
    Macalalad, Alexander R.
    Guerin, Annie
    ADVANCES IN THERAPY, 2017, 34 (07) : 1673 - 1685
12345